Facilitated Subcutaneous Immunoglobulin Treatment Patterns in Pediatric Patients with Primary Immunodeficiency Diseases

References

• Chapel H , PrevotJ, GasparHBet al. Primary immune deficiencies - principles of care. Front. Immunol.5, 627 (2014).
   PubMed Web of Science ®Google Scholar
• Perez EE , OrangeJS, BonillaFet al. Update on the use of immunoglobulin in human disease: a review of evidence. J. Allergy Clin. Immunol.139(3S), S1–S46 (2017).
   PubMed Web of Science ®Google Scholar
• Wasserman RL , MelamedI, SteinMRet al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J. Allergy Clin. Immunol.130(4), 951–7.e11 (2012).
   PubMed Web of Science ®Google Scholar
• Wasserman RL . Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. Immunotherapy9(12), 1035–1050 (2017).
   PubMed Web of Science ®Google Scholar
• Wasserman RL , MelamedI, KobrynskiLet al. Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability. Immunotherapy8(10), 1175–1186 (2016).
   PubMed Web of Science ®Google Scholar
• Wasserman RL , MelamedI, SteinMRet al. Long-term tolerability, safety, and efficacy of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulin for primary immunodeficiency. J. Clin. Immunol.36(6), 571–582 (2016).
   PubMed Web of Science ®Google Scholar
• McMurtry CM , TaddioA, NoelMet al. Exposure-based interventions for the management of individuals with high levels of needle fear across the lifespan: a clinical practice guideline and call for further research. Cogn. Behav. Ther.45(3), 217–235 (2016).
   PubMed Web of Science ®Google Scholar
• Espanol T , PrevotJ, DrabwellJ, SondhiS, OldingL. Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment. Patient Prefer. Adherence8, 621–629 (2014).
   PubMed Web of Science ®Google Scholar
• Health Quality Ontario . Home-based subcutaneous infusion of immunoglobulin for primary and secondary immunodeficiencies: a health technology assessment. Ont. Health Technol. Assess. Ser.17(16), 1–86 (2017).
   Google Scholar
• Wasserman RL . Personalized therapy: immunoglobulin replacement for antibody deficiency. Immunol Allergy Clin. North Am.39(1), 95–111 (2019).
   PubMed Web of Science ®Google Scholar
• Franklin JM , SchneeweissS. When and how can real world data analyses substitute for randomized controlled trials?Clin. Pharmacol. Ther.102(6), 924–933 (2017).
   PubMed Web of Science ®Google Scholar
• Agencja Oceny Technologii Medycznych i Taryfikacji . Rekomendacja nr 97/2015 z dnia 14 grudnia 2015 w sprawie objęcia refundacją produktu leczniczego HyQvia. Leczenie pierwotnych niedoborów odporności (PNO) u pacjentów dorosłych (2015). www.onkologia-online.pl/upload/12/191/RP_97_2015_HyQvia.pdf
   Google Scholar
• Ministry of Health . Leczenie pierwotnych niedoborów odporności u dzieci (2018). www.gov.pl/attachment/fe245c15-c117-4931-8a43-da7e7f4a49a9
   Google Scholar
• European Medicines Agency . HyQvia 100 mg/ml solution for infusion for subcutaneous use. Summary of product characteristics (2023). https://www.ema.europa.eu/en/documents/product-information/hyqvia-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency . Cuvitru 200 mg/ml solution for subcutaneous injection. Summary of product characteristics (2012). https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/37665/characteristic
   Google Scholar
• European Society for Immunodeficiencies . Diagnostic Criteria PID (2022). https://esid.org/Education/Diagnostic-Criteria-PID
   Google Scholar
• Wasserman RL . HyQvia Experience Study Group. Clinical practice experience with HyQvia in adults using alternative dosing regimens and pediatric patients: a retrospective study. Adv. Ther.37, 1536–1549 (2020).
   PubMed Web of Science ®Google Scholar
• Shabaninejad H , AsgharzadehA, RezaeiN, RezapoorA. A comparative study of intravenous immunoglobulin and subcutaneous immunoglobulin in adult patients with primary immunodeficiency diseases: a systematic review and meta-analysis. Expert Rev. Clin. Immunol.12(5), 595–602 (2016).
   PubMed Web of Science ®Google Scholar
• Wasserman RL . Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J. Clin. Immunol.32(6), 1153–1164 (2012).
   PubMed Web of Science ®Google Scholar
• Hodkinson JP , LucasM, LeeMet al. Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients. Clin. Exp. Immunol.181(1), 179–187 (2015).
   PubMed Web of Science ®Google Scholar
• Baumann U , FasshauerM, PauschCet al. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases. Immunotherapy.14(2), 135–143 (2022).
   PubMed Web of Science ®Google Scholar
• Borte M , HanitschLG, MahlaouiNet al. Facilitated subcutaneous immunoglobulin treatment in patients with immunodeficiencies: the FIGARO study. J. Clin. Immunol.10, 1–13 (2023).
   Google Scholar
• Gruenemeier P , ErnstC, PalagashviliT, DuffK. P259 Retrospective review of needle length and clinical considerations during hyaluronidase-facilitated subcutaneous administration of immunoglobulin (IGHY). Ann. Allergy Asthma Immunol.117(Suppl. 5), S99 (2016).
   PubMed Web of Science ®Google Scholar
• Gruenemeier P , ErnstC, WhiteC, DuffK. P255 Real-world pediatric experience with hyaluronidase-facilitated subcutaneous immunoglobulin (IGHY) infusion parameters. Ann. Allergy Asthma Immunol.117(Suppl. 5), S98 (2016).
   Web of Science ®Google Scholar
• Stubbs A , BangsC, ShillitoeBet al. Bronchiectasis and deteriorating lung function in agammaglobulinaemia despite immunoglobulin replacement therapy. Clin. Exp. Immunol.191, 212–219 (2018).
   PubMed Web of Science ®Google Scholar
• Quartier P , DebréM, DeBlic Jet al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J. Pediatr.134(5), 589–596 (1999).
   PubMed Web of Science ®Google Scholar
• Ciznar P , RoderickM, SchneiderováHet al. Real-world safety and tolerability of facilitated subcutaneous immunoglobulin in pediatric patients with primary immunodeficiency diseases: interim analysis from a post-authorization study in Europe. Selected abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 virtual annual meeting: Immune Deficiency and Dysregulation North American Conference. J. Clin. Immunol.41(Suppl. 1), 163 (2021).
   PubMed Web of Science ®Google Scholar